IGF::OT::IGF MIND CAP: MONITORING FOR COGNITIVE IMPAIRMENT AND DYSFUNCTION IN CANCER PATIENTS

IGF::OT::IGF Mind CAP：监测癌症患者的认知障碍和功能障碍

• 批准号: 9362129
• 负责人: LISA HOLT
• 金额: $ 22.5万
• 依托单位: INTELLIGENT AUTOMATION, INC.
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-19 至 2017-06-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9362129
• 关键词: Address; Affect; Algorithms; Android; Architecture; Area; Breast Cancer Patient; Cancer Patient; Client; Clinical; Cognitive; Collaborations; Computer software; Data; Data Analyses; Detection; Development; Documentation; Feedback; Focus Groups; Functional disorder; Health Personnel; Healthcare; Home environment; Impaired cognition; Impairment; Intervention; Interview; Literature; Metadata; Methods; Mind; Monitor; Oncologist; Online Systems; Patient observation; Patients; Pattern; Performance; Pharmacologic Substance; Phase; Population; Production; Provider; Recommendation; Research; Research Contracts; Research Personnel; Risk; Schedule; Scoring Method; System; Target Populations; Testing; Time; anticancer research; career; cognitive testing; commercialization; design; experience; handheld mobile device; improved; innovation; malignant breast neoplasm; mobile application; oncology; programs; prototype; software systems; success; trend analysis; usability

IAI, with our partner NTI, proposes to develop the MIND CAP system – Monitoring cognitive Impairment and Dysfunction in Cancer Patients. We will employ a quantitative approach to select existing cognitive tests from the clinical literature that are sensitive enough to detect cognitive decrements in the domains most relevant to the breast cancer population. In collaboration with our expert panel of oncologist subject matter experts we will identify the cognitive domains most affected. The resulting system will include a web‐based portal for test administration and result monitoring, and a mobile patient application for taking tests and self‐monitoring. Innovative features include: Cognitive tests quantitatively selected through use of an innovative algorithm to assess relevant cognitive domains; Sensitive tests capable of detecting cognitive impairments experienced by patients; Accessible tests that can be taken in non‐clinical settings; Brief tests (no more than a 10‐15 minutes session/week); Adaptive testing utilizing personal baselines, enabling repeated use of a test and detection of significant decline through trend analysis; Mobile interface reminding patients to take tests, allowing logging of cognitive complaints, and alerting them to significant cognitive decline; A provider portal allowing providers or researchers to assign tests, monitor progress, and be alerted to significant cognitive decline.

IAI，与我们的合作伙伴NTI一起，提出了发展思维上限系统的建议 - 监测癌症患者的认知障碍和功能障碍。我们将采用一种定量方法从临床文献中选择现有的认知测试，这些测试足够敏感，可以检测到与乳腺癌种群最相关的领域的认知降低。在与我们的肿瘤学主题专家专家小组合作的情况下，我们将确定受影响最大的认知领域。最终的系统将包括基于Web的门户进行测试管理和结果监视，以及用于进行测试和自我监控的移动患者应用程序。创新的特征包括：通过使用创新算法评估相关认知领域的认知测试。能够检测患者经历的认知障碍的敏感测试；可以在非临床设置中进行的可访问测试；简短测试（每周不超过10-15分钟的会议）；利用个人基准的自适应测试，可以重复使用测试并通过趋势分析检测显着下降；移动界面提醒患者参加测试，允许记录认知投诉，并提醒他们大幅下降；提供商门户网站允许提供者或研究人员分配测试，监控进度并受到警告的认知能力下降。